Literature DB >> 16035732

Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia.

Sona Peková1, Jana Marková, Petr Pajer, Michal Dvorák, Petr Cetkovský, Jirí Schwarz.   

Abstract

BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) can relapse even after aggressive therapy and autografts. It is commonly assumed that to prevent relapse the level of minimal residual disease (MRD) should be as low as possible. To evaluate MRD, highly sensitive quantitative assays are needed. AIM: The aim of the study was to develop a robust and sensitive method for detection of the clonal immunoglobulin heavy-chain variable (IgV(H)) rearrangement in CLL and to introduce a highly sensitive and specific methodology for MRD monitoring in patients with CLL who undergo intensive treatment.
METHODS: As a prerequisite for MRD detection, touch-down reverse transcriptase (RT)-PCR using degenerate primers were used for the diagnostic identification of (H) gene rearrangement(s). For quantitative MRD detection in 18 patients, we employed a real-time RT-PCR assay (RQ-PCR) making use of patient-specific primers and the cost-saving Sybr-Green reporter dye (SG). For precise calibration of RQ-PCR, patient-specific IgV(H) sequences were cloned.
RESULTS: Touch-down RT-PCR with degenerate primers allowed the successful detection of IgV(H) clonal rearrangement(s) in 252 of 257 (98.1%) diagnostic samples. Biallelic rearrangements were found in 27 of 252 (10.7%) cases. Degenerate primers used for the identification of clonal expansion at diagnosis were not sensitive enough for MRD detection. In contrast, our RQ-PCR assay using patient-specific primers and SG reached the sensitivity of 10(-)(6). We demonstrated MRD in each patient tested, including four of four patients in complete remission following autologous hematopoietic stem cell transplantation (HSCT) and three of three following allogeneic 'mini'-HSCT. Increments in MRD might herald relapse; aggressive chemotherapy could induce molecular remission.
CONCLUSIONS: Our touch-down RT-PCR has higher efficiency to detect clonal IgV(H) rearrangements including the biallelic ones. MRD quantitation of IgV(H) expression using SG-based RQ-PCR represents a highly specific, sensitive, and economic alternative to the current quantitative methods.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16035732     DOI: 10.2165/00066982-200509010-00004

Source DB:  PubMed          Journal:  Mol Diagn        ISSN: 1084-8592


  39 in total

Review 1.  Chronic lymphocytic leukaemia: risk-adapted therapy.

Authors:  D K Hossfeld
Journal:  Ann Oncol       Date:  2000       Impact factor: 32.976

Review 2.  Recent advances in the molecular biology and immunobiology of chronic lymphocytic leukemia.

Authors:  Manlio Ferrarini; Nicholas Chiorazzi
Journal:  Semin Hematol       Date:  2004-07       Impact factor: 3.851

Review 3.  Chronic lymphocytic leukemia.

Authors:  C Rozman; E Montserrat
Journal:  N Engl J Med       Date:  1995-10-19       Impact factor: 91.245

4.  Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells.

Authors:  U Klein; Y Tu; G A Stolovitzky; M Mattioli; G Cattoretti; H Husson; A Freedman; G Inghirami; L Cro; L Baldini; A Neri; A Califano; R Dalla-Favera
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

5.  Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.

Authors:  A Noy; R Verma; M Glenn; P Maslak; Z U Rahman; J R Keenan; M Weiss; D Filippa; A D Zelenetz
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

6.  Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR.

Authors:  B Cassinat; F Zassadowski; N Balitrand; C Barbey; J D Rain; P Fenaux; L Degos; M Vidaud; C Chomienne
Journal:  Leukemia       Date:  2000-02       Impact factor: 11.528

7.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

8.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

Authors:  S Slavin; A Nagler; E Naparstek; Y Kapelushnik; M Aker; G Cividalli; G Varadi; M Kirschbaum; A Ackerstein; S Samuel; A Amar; C Brautbar; O Ben-Tal; A Eldor; R Or
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

9.  Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts.

Authors:  Andy C Rawstron; Michael J Green; Anita Kuzmicki; Ben Kennedy; James A L Fenton; Paul A S Evans; Sheila J M O'Connor; Stephen J Richards; Gareth J Morgan; Andrew S Jack; Peter Hillmen
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

10.  IgVH genes from different anatomical regions, with different histopathological patterns, of a rheumatoid arthritis patient suggest cyclic re-entry of mature synovial B-cells in the hypermutation process.

Authors:  M M Souto-Carneiro; V Krenn; R Hermann; A König; H K Müller-Hermelink
Journal:  Arthritis Res       Date:  2000-05-19
View more
  3 in total

Review 1.  Assessing minimal residual disease in chronic lymphocytic leukemia.

Authors:  Andy C Rawstron; Peter Hillmen
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

2.  Identification of leukemia-specific fusion gene transcripts with a novel oligonucleotide array.

Authors:  Sung-Min Chun; Yoo-Li Kim; Hee Baeg Choi; Yong-Taek Oh; Yoo-Jin Kim; Seok Lee; Tai-Gyu Kim; Eun Gyeong Yang; Yong-Keun Park; Dong-Wook Kim; Byoung-Don Han
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

3.  Quantitation of minimal residual disease in patients with chronic lymphocytic leukemia using locked nucleic acid-modified, fluorescently labeled hybridization probes and real-time PCR technology.

Authors:  Sona Peková; Ludmila Bezdícková; Lukás Smolej; Tomás Kozák; Ivana Hochová; Pavel Zák; Lucie Tomsíková; Miroslav Průcha
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.